Print

Millennium: The Takeda Oncology Company and Seattle Genetics, Inc. (SGEN) Highlight Data From ADCETRIS® (Brentuximab Vedotin) Trial in Patients With Newly Diagnosed Systemic Anaplastic Large Cell Lymphoma  
10/1/2012 11:08:02 AM

CAMBRIDGE, Mass. & BOTHELL, Wash.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), and Seattle Genetics, Inc. (Nasdaq: SGEN), today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP1 or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas. Data were presented from one arm, which evaluates brentuximab vedotin in sequence with CHOP in patients with newly diagnosed systemic anaplastic large cell lymphoma (sALCL), a subtype of mature T- and NK cell lymphomas. The data were reported during an oral presentation at the ESMO 2012 Congress (European Society for Medical Oncology) being held September 28 – October 2, 2012 in Vienna, Austria.
//-->